eligibility_summary
Include: Adults ≥18 with r/r B‑precursor ALL (MRD+, ≥100 d post‑allo‑HCT, isolated asymptomatic CNS relapse allowed), ECOG 0–2, adequate renal/hepatic/cardiac/pulmonary function (CrCl ≥60, EF ≥50, QTc ≤500), CD19+ if prior blinatumomab, neg pregnancy test, contraception, consent. Exclude: dasatinib intolerance/allergy, BM blasts >75%, symptomatic CNS‑3 or other CNS/cardiac disorders, immunodeficiency or active infection (incl HIV/HBV/HCV), recent chemo/TKI/steroids/IS/GVHD tx/live vaccine, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b, single-arm trial in adults with relapsed/refractory B‑cell ALL evaluating brexucabtagene autoleucel (Tecartus) plus pulsed dasatinib. Brexucabtagene autoleucel is an autologous anti‑CD19 CAR‑T cell therapy (cellular immunotherapy) that recognizes CD19 and kills malignant B cells via CAR-mediated activation and cytotoxic effector pathways. Dasatinib is an oral small‑molecule tyrosine kinase inhibitor (BCR‑ABL/Src family, also c‑KIT/PDGFR) given 100 mg daily for 3 days/week starting ~Day 4 post‑CAR‑T to modulate CAR‑T activity by transiently inhibiting proximal Src/Lck signaling and, in Ph+ ALL, to suppress BCR‑ABL. Target cells/pathways: CD19+ B‑ALL blasts, CAR/T‑cell receptor signaling (Src/Lck), BCR‑ABL oncogenic signaling (if present).